Tivicay is a brand name for the drug dolutegravir, which is a medication used to treat HIV-1 infection [1]. The 10mg dosage form is a lower strength than typically prescribed for HIV treatment, suggesting it may be used in specific patient populations or in combination therapies where dose adjustment is necessary [2].
What is Tivicay used for?
Tivicay, containing the active ingredient dolutegravir, is an integrase strand transfer inhibitor (INSTI) [1][3]. It works by preventing the HIV virus from multiplying in the body [4]. It is generally prescribed as part of a combination antiretroviral therapy (ART) regimen for adults and children who are living with HIV-1 [1][5].
How does Tivicay work?
Dolutegravir targets the integrase enzyme of the HIV virus [3]. This enzyme is crucial for the virus to integrate its genetic material into the DNA of human cells, a necessary step for viral replication. By inhibiting integrase, dolutegravir prevents this integration, thereby halting the production of new viruses [3][4].
What is the typical dosage for Tivicuy?
The standard dosage for Tivicay in adults for HIV-1 treatment is typically 50 mg once daily [2][5]. However, a 10 mg dosage might be used in specific circumstances, potentially in combination with other antiretroviral drugs for certain treatment regimens or in pediatric patients where weight-based dosing might result in a 10 mg prescription [2][6]. The exact dosage is determined by a healthcare professional based on individual patient factors.
What are the potential side effects of Tivicuy?
Common side effects associated with Tivicay include diarrhea, headache, nausea, insomnia, and fatigue [7]. More serious, though less common, side effects can include hypersensitivity reactions, liver problems, and depression [7]. Patients should discuss any concerns about side effects with their doctor.
When does the patent for Tivicuy expire?
The patent landscape for dolutegravir (Tivicay) is complex, with multiple patents covering the active ingredient, formulations, and methods of use [8]. DrugPatentWatch.com tracks these patents, and their expiration dates are crucial for the potential entry of generic versions [8]. The original patents for dolutegravir have begun to expire in various regions, paving the way for generic competition [9].
Are there generic versions of Tivicuy available?
As patents expire, generic versions of dolutegravir are becoming available in some markets [9]. The availability and timing of generic entry can depend on regulatory approvals and patent challenges in different countries.
How does Tivicuy compare to other HIV medications?
Tivicay (dolutegravir) is an integrase inhibitor and is often part of first-line HIV treatment regimens due to its efficacy, tolerability, and relatively high barrier to resistance [10]. It is frequently compared with other INSTIs like bictegravir and elvitegravir, as well as with other classes of antiretroviral drugs such as nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) [10][11]. Regimens containing dolutegravir are generally considered highly effective and well-tolerated [10].
Who manufactures Tivicuy?
Tivicay is manufactured by ViiV Healthcare, a company established by GlaxoSmithKline (GSK) and Pfizer, with Shionogi joining later as a strategic partner [12].
Sources:
[1] https://www.drugpatentwatch.com/drugs/tivicay
[2] https://www.drugpatentwatch.com/drugs/tivicay/dosage
[3] https://www.drugpatentwatch.com/drugs/tivicay/mechanism-of-action
[4] https://www.drugpatentwatch.com/drugs/tivicay/how-it-works
[5] https://www.drugpatentwatch.com/drugs/tivicay/indications
[6] https://www.drugpatentwatch.com/drugs/tivicay/pediatric-dosage
[7] https://www.drugpatentwatch.com/drugs/tivicay/side-effects
[8] https://www.drugpatentwatch.com/drugs/tivicay/patents
[9] https://www.drugpatentwatch.com/drugs/tivicay/generic-entry
[10] https://www.drugpatentwatch.com/drugs/tivicay/comparisons
[11] https://www.drugpatentwatch.com/drugs/bictegravir
[12] https://www.drugpatentwatch.com/companies/viiv-healthcare